Lupin Limited services

Lupin`s IPMG is responsible for creating, securing, and leveraging a portfolio of high-value patents, products, and research pipeline projects. IPMG has also successfully managed patent challenges in courts and patent offices around the world.

Lupin’s generic R&D pipeline is aimed at developing a comprehensive portfolio of high entry barrier products that address unmet patient needs. Our track record of successful ANDA filings and approvals has garnered us leadership in several chronic therapy areas such respiratory, diabetes and cardiovascular in India, and hypertension and calcium blockers in the US.

Lupin operates in a highly competitive, demanding, dynamic and diverse markets, in which we need to continuously distinguish ourselves from our peers and competitions through differentiated products. We consider research in advanced drug delivery technologies as the cradle for ideas and innovations for the development of high entry barrier products in inhalation, injectable, ophthalmic and oral space. Such technologies and products with high degree of complexities not only act as a key differentiator but also serve as growth drivers for the company and at the same time transform the patient experience.

The NDDD team has developed a pipeline of highly differentiated and innovative new chemical entities in focused therapeutic areas of Oncology, Immunology and Metabolic Disorders.